US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
DK2371865T3
(en)
|
2006-04-07 |
2017-10-23 |
Aerpio Therapeutics Inc |
Antibodies that bind human protein tyrosine phosphatase beta (HPTP-β) and uses thereof
|
KR20110009095A
(ko)
|
2008-03-03 |
2011-01-27 |
더 유니버시티 오브 마이애미 |
동종 이계 암 세포-기반 면역 요법
|
KR20210060670A
(ko)
|
2008-12-09 |
2021-05-26 |
제넨테크, 인크. |
항-pd-l1 항체 및 t 세포 기능을 향상시키기 위한 그의 용도
|
CA3067609A1
(en)
|
2009-09-03 |
2011-03-10 |
Merck Sharp & Dohme Corp. |
Anti-gitr antibodies
|
US20130017199A1
(en)
*
|
2009-11-24 |
2013-01-17 |
AMPLIMMUNE ,Inc. a corporation |
Simultaneous inhibition of pd-l1/pd-l2
|
IL300733A
(en)
|
2010-03-05 |
2023-04-01 |
Univ Johns Hopkins |
Compositions and methods for antibodies and fusion proteins targeting immune modulation
|
PL3604339T3
(pl)
|
2011-01-14 |
2021-12-27 |
The Regents Of The University Of California |
Terapeutyczne przeciwciała przeciwko białku ror-1 i sposoby ich zastosowania
|
CN110038135B
(zh)
|
2011-03-17 |
2021-03-05 |
伯明翰大学 |
重新定向的免疫治疗
|
EP3670536A3
(en)
*
|
2011-04-01 |
2020-10-07 |
Universität Stuttgart |
Recombinant tnf ligand family member polypeptides with antibody binding domain and uses thereof
|
SG185920A1
(en)
|
2011-05-27 |
2012-12-28 |
Abbott Biotherapeutics Corp |
Dac hyp compositions and methods
|
SI2768524T1
(sl)
*
|
2011-10-17 |
2022-09-30 |
Io Biotech Aps |
Imunoterapija na osnovi PD-L1
|
CN104254778A
(zh)
*
|
2012-02-10 |
2014-12-31 |
西雅图遗传学公司 |
Cd30+癌症的检测和治疗
|
IN2014MN02164A
(zh)
|
2012-04-27 |
2015-08-28 |
Cytomx Therapeutics Inc |
|
EP4219536A3
(en)
*
|
2012-04-30 |
2023-08-23 |
Biocon Limited |
Targeted/immunomodulatory fusion proteins and methods for making same
|
CA2889298C
(en)
|
2012-11-30 |
2024-01-02 |
Anton Belousov |
Identification of patients in need of pd-l1 inhibitor cotherapy
|
US9834610B2
(en)
|
2013-01-31 |
2017-12-05 |
Thomas Jefferson University |
Fusion proteins for modulating regulatory and effector T cells
|
US9657082B2
(en)
|
2013-01-31 |
2017-05-23 |
Thomas Jefferson University |
PD-L1 and PD-L2-based fusion proteins and uses thereof
|
WO2015116178A1
(en)
*
|
2014-01-31 |
2015-08-06 |
Thomas Jefferson University |
Fusion proteins for modulating regulatory and effector t cells
|
EP2951209A4
(en)
|
2013-01-31 |
2016-06-22 |
Univ Jefferson |
CD40 OX40 AGONIST FUSION PROTEIN AND USES THEREOF
|
EP3936137A1
(en)
|
2013-02-07 |
2022-01-12 |
The General Hospital Corporation |
Methods for expansion or depletion of t-regulatory cells
|
RU2662991C2
(ru)
*
|
2013-03-12 |
2018-07-31 |
Биокон Лтд. |
Слитые иммуномодулирующие белки и способы их получения
|
WO2014160490A1
(en)
*
|
2013-03-13 |
2014-10-02 |
Genetech, Inc. |
Antibody formulations
|
WO2014168715A1
(en)
*
|
2013-04-08 |
2014-10-16 |
R-Pharm Overseas, Inc. |
B7 ligands/cd20 inhibitor composition and use thereof
|
CN105209054A
(zh)
|
2013-04-18 |
2015-12-30 |
阿尔莫生物科技股份有限公司 |
使用白细胞介素-10治疗疾病和病症的方法
|
CN105722859B
(zh)
|
2013-07-25 |
2021-05-07 |
西托姆克斯治疗公司 |
多特异性抗体、多特异性可活化抗体及其使用方法
|
WO2015027082A1
(en)
|
2013-08-22 |
2015-02-26 |
Acceleron Pharma, Inc. |
Tgf-beta receptor type ii variants and uses thereof
|
US9540440B2
(en)
|
2013-10-30 |
2017-01-10 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
MX2016005915A
(es)
*
|
2013-11-11 |
2016-12-16 |
Armo Biosciences Inc |
Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
|
WO2015089283A1
(en)
|
2013-12-11 |
2015-06-18 |
Cytomx Therapeutics, Inc. |
Antibodies that bind activatable antibodies and methods of use thereof
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
WO2015120198A1
(en)
*
|
2014-02-05 |
2015-08-13 |
Cedars-Sinai Medical Center |
Methods and compositions for treating cancer and infectious diseases
|
JP6731346B2
(ja)
*
|
2014-02-10 |
2020-07-29 |
メルク パテント ゲーエムベーハー |
標的TGFβ阻害
|
EP3132802B1
(en)
*
|
2014-02-21 |
2020-06-17 |
IDAC Theranostics, Inc. |
Therapeutic agent for solid cancer
|
AU2015222917A1
(en)
|
2014-02-27 |
2016-09-15 |
Lycera Corporation |
Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
|
US20150307620A1
(en)
*
|
2014-04-16 |
2015-10-29 |
University Of Connecticut |
Linked immunotherapeutic agonists that costimulate multiple pathways
|
JP6728061B2
(ja)
|
2014-05-05 |
2020-07-22 |
リセラ・コーポレイションLycera Corporation |
RORγアゴニストとして用いるテトラヒドロキノリンスルホンアミド及び関連化合物ならびに疾患の治療
|
EP3209641A4
(en)
|
2014-05-05 |
2018-06-06 |
Lycera Corporation |
Benzenesulfonamido and related compounds for use as agonists of ror and the treatement of disease
|
CN103965364B
(zh)
*
|
2014-05-19 |
2016-06-08 |
亚飞(上海)生物医药科技有限公司 |
一种人源pdl2hsa系列融合蛋白及其制备与应用
|
WO2015178746A1
(ko)
*
|
2014-05-23 |
2015-11-26 |
주식회사 제넥신 |
Pd-l1 융합 단백질 및 이의 용도
|
EP3498295A1
(en)
|
2014-05-28 |
2019-06-19 |
Agenus Inc. |
Anti-gitr antibodies and methods of use thereof
|
EP3610924B1
(en)
|
2014-06-06 |
2021-11-03 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
JP6715491B2
(ja)
*
|
2014-06-11 |
2020-07-01 |
Idacセラノスティクス株式会社 |
免疫チェックポイント制御剤の副作用低減方法
|
KR102493543B1
(ko)
*
|
2014-07-21 |
2023-01-30 |
데리니아, 인크. |
자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자
|
CN107108738A
(zh)
|
2014-07-25 |
2017-08-29 |
西托姆克斯治疗公司 |
抗cd3抗体、可活化抗cd3抗体、多特异性抗cd3抗体、多特异性可活化抗cd3抗体及其使用方法
|
SI3482766T1
(sl)
|
2014-08-11 |
2020-09-30 |
Delinia, Inc. |
Spremenjene variante IL-2, ki selektivno aktivirajo regulatorne T celice za zdravljenje avtoimunskih bolezni
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
BR112017004393A2
(pt)
|
2014-09-15 |
2018-02-27 |
Genentech Inc |
formulações de anticorpo
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
RS61870B1
(sr)
|
2014-11-14 |
2021-06-30 |
Hoffmann La Roche |
Antigen vezujući molekuli koji sadrže trimer liganda iz tnf familije
|
WO2016118577A1
(en)
*
|
2015-01-22 |
2016-07-28 |
Medimmune, Llc |
Thymosin-beta-four fusion proteins
|
MA41460A
(fr)
|
2015-02-03 |
2017-12-12 |
Oncomed Pharm Inc |
Agents de liaison à la tnfrsf et leurs utilisations
|
US11000548B2
(en)
|
2015-02-18 |
2021-05-11 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
US11596652B2
(en)
|
2015-02-18 |
2023-03-07 |
Enlivex Therapeutics R&D Ltd |
Early apoptotic cells for use in treating sepsis
|
US11497767B2
(en)
|
2015-02-18 |
2022-11-15 |
Enlivex Therapeutics R&D Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
US11318163B2
(en)
|
2015-02-18 |
2022-05-03 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
US11304976B2
(en)
|
2015-02-18 |
2022-04-19 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
WO2016132366A1
(en)
|
2015-02-18 |
2016-08-25 |
Enlivex Therapeutics Ltd. |
Combination immune therapy and cytokine control therapy for cancer treatment
|
CN107683333A
(zh)
|
2015-03-11 |
2018-02-09 |
塞勒克提斯公司 |
用于工程化同种异体t细胞以增加其在患者中的持久性和/或移植成活率的方法
|
SG11201707383PA
(en)
|
2015-03-13 |
2017-10-30 |
Cytomx Therapeutics Inc |
Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
|
WO2016156291A1
(en)
|
2015-03-31 |
2016-10-06 |
F. Hoffmann-La Roche Ag |
Antigen binding molecules comprising a trimeric tnf family ligand
|
US11215616B2
(en)
|
2015-04-10 |
2022-01-04 |
National Institutes Of Health (Nih), (Dhhs), U.S. Government |
Methods of determining patient populations amenable to immunomodulatory treatment of cancer
|
RS61943B1
(sr)
|
2015-04-17 |
2021-07-30 |
Alpine Immune Sciences Inc |
Imunomodulatorni proteini sa prilagodljivim afinitetima
|
US10857181B2
(en)
|
2015-04-21 |
2020-12-08 |
Enlivex Therapeutics Ltd |
Therapeutic pooled blood apoptotic cell preparations and uses thereof
|
AU2016258977C1
(en)
*
|
2015-05-04 |
2022-07-14 |
Pieris Pharmaceuticals Gmbh |
Anti-cancer fusion polypeptide
|
EP3292119A4
(en)
|
2015-05-05 |
2018-10-03 |
Lycera Corporation |
DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
|
KR20180015650A
(ko)
|
2015-05-07 |
2018-02-13 |
아게누스 인코포레이티드 |
항-ox40 항체 및 이의 사용 방법
|
US10690674B2
(en)
|
2015-06-03 |
2020-06-23 |
Bristol-Myers Squibb Company |
Anti-GITR antibodies for cancer diagnostics
|
AU2016276947A1
(en)
|
2015-06-11 |
2017-12-14 |
Lycera Corporation |
Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
|
CN108368170B
(zh)
|
2015-07-13 |
2022-04-15 |
西托姆克斯治疗公司 |
抗pd-1抗体、可活化抗pd-1抗体及其使用方法
|
MX2017016844A
(es)
|
2015-07-16 |
2018-08-15 |
Biokine Therapeutics Ltd |
Composiciones y procedimientos para tratar cancer.
|
CN108136025B
(zh)
|
2015-07-16 |
2022-09-06 |
比奥克斯塞尔医疗股份有限公司 |
一种使用免疫调节治疗癌症的新颖方法
|
US11466093B2
(en)
|
2015-07-27 |
2022-10-11 |
The General Hospital Corporation |
Antibody derivatives with conditionally enabled effector function
|
CA2994413A1
(en)
|
2015-08-04 |
2017-02-09 |
Acceleron Pharma, Inc. |
Methods for treating myeloproliferative disorders
|
CN108025040A
(zh)
|
2015-08-25 |
2018-05-11 |
阿尔莫生物科技股份有限公司 |
使用白介素-10治疗疾病和病症的方法
|
IL307276A
(en)
|
2015-08-28 |
2023-11-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
US20200231652A1
(en)
*
|
2015-08-31 |
2020-07-23 |
National Research Council Of Canada |
Tgf-b-receptor ectodomain fusion molecules and uses thereof
|
WO2017048824A1
(en)
*
|
2015-09-14 |
2017-03-23 |
Compass Therapeutics Llc |
COMPOSITIONS AND METHODS FOR TREATING CANCER VIA ANTAGONISM OF THE CD155/TIGIT PATHWAY AND TGF-β
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
SG10201913597VA
(en)
|
2015-10-01 |
2020-02-27 |
Heat Biologics Inc |
Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
|
US10287352B2
(en)
|
2015-10-02 |
2019-05-14 |
Hoffman-La Roche Inc. |
Bispecific antibodies specific for PD1 and TIM3
|
US20170107510A1
(en)
*
|
2015-10-14 |
2017-04-20 |
Batu Biologics, Inc. |
Dna nanoparticle based checkpoint inhibitors
|
KR20180083868A
(ko)
|
2015-10-30 |
2018-07-23 |
알레타 바이오쎄라퓨틱스, 인크. |
종양 형질도입용 조성물 및 방법
|
EP3368559A4
(en)
*
|
2015-10-30 |
2020-01-15 |
Aleta Biotherapeutics Inc. |
COMPOSITIONS AND METHODS FOR TREATING CANCER
|
WO2017087784A1
(en)
|
2015-11-18 |
2017-05-26 |
Duke University |
Tumor infiltrating lymphocytes for treatment of cancer
|
US11213586B2
(en)
|
2015-11-19 |
2022-01-04 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR)
|
KR20180083944A
(ko)
|
2015-12-02 |
2018-07-23 |
아게누스 인코포레이티드 |
항체 및 이의 사용 방법
|
EP3399989B1
(en)
|
2015-12-16 |
2023-08-09 |
Merck Sharp & Dohme LLC |
Anti-lag3 antibodies and antigen-binding fragments
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
WO2017134592A1
(en)
*
|
2016-02-03 |
2017-08-10 |
Biocon Limited |
Anti-cd20/immunomodulatory fusion proteins and methods for making same
|
US11730761B2
(en)
|
2016-02-18 |
2023-08-22 |
Enlivex Therapeutics Rdo Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
US11542332B2
(en)
|
2016-03-26 |
2023-01-03 |
Bioatla, Inc. |
Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
EP3231813A1
(en)
|
2016-03-29 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Trimeric costimulatory tnf family ligand-containing antigen binding molecules
|
CN116715767A
(zh)
|
2016-05-13 |
2023-09-08 |
综合医院公司 |
拮抗性抗肿瘤坏死因子受体超家族抗体
|
US11352413B2
(en)
|
2016-05-17 |
2022-06-07 |
Albert Einstein College Of Medicine |
Engineered PD-1 variants
|
MX2018014387A
(es)
|
2016-05-27 |
2019-03-14 |
Agenus Inc |
Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos.
|
WO2018009916A1
(en)
|
2016-07-07 |
2018-01-11 |
The Board Of Trustees Of The Leland Stanford Junior University |
Antibody adjuvant conjugates
|
KR20240014617A
(ko)
*
|
2016-09-27 |
2024-02-01 |
에피센트알엑스, 인코포레이티드 |
면역조정 융합 단백질
|
US10844119B2
(en)
|
2016-10-11 |
2020-11-24 |
Agenus Inc. |
Anti-LAG-3 antibodies and methods of use thereof
|
WO2018071911A1
(en)
*
|
2016-10-14 |
2018-04-19 |
Emory University |
Nanoparticles having molecules that bind or block pd-l1 and uses in treating cancer
|
US20200038509A1
(en)
*
|
2016-10-14 |
2020-02-06 |
Baylor College Of Medicine |
Radiofrequency field hyperthermia and solid tumor immunomodulation
|
KR20190083656A
(ko)
|
2016-11-08 |
2019-07-12 |
데리니아, 인크. |
자가면역 질환의 치료를 위한 il-2 변이체
|
AU2017359467A1
(en)
|
2016-11-09 |
2019-05-02 |
Agenus Inc. |
Anti-OX40 antibodies, anti-GITR antibodies, and methods of use thereof
|
EP3544601B1
(en)
*
|
2016-11-23 |
2024-03-20 |
Translational Drug Development, LLC |
A composition comprising a benzamide and a tnfrsf agonist binding to 4-1bb or gitr, and the use thereof in the treatment of cancer.
|
WO2018102536A1
(en)
|
2016-11-30 |
2018-06-07 |
Oncomed Pharmaceuticals, Inc. |
Methods for treatment of cancer comprising tigit-binding agents
|
ES2961666T3
(es)
|
2016-12-03 |
2024-03-13 |
Juno Therapeutics Inc |
Métodos para determinar la dosificación de células CAR-T
|
CA3045338A1
(en)
|
2016-12-05 |
2018-06-14 |
Juno Therapeutics, Inc. |
Production of engineered cells for adoptive cell therapy
|
US11299530B2
(en)
|
2017-01-05 |
2022-04-12 |
Kahr Medical Ltd. |
SIRP alpha-CD70 fusion protein and methods of use thereof
|
HRP20220230T1
(hr)
*
|
2017-01-05 |
2022-04-29 |
Kahr Medical Ltd. |
Sirp1 alfa-41bbl fuzijski protein i metoda njegove upotrebe
|
DK3565579T3
(da)
*
|
2017-01-05 |
2023-09-04 |
Kahr Medical Ltd |
Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
|
WO2018127916A1
(en)
*
|
2017-01-05 |
2018-07-12 |
Kahr Medical Ltd. |
A pd1-cd70 fusion protein and methods of use thereof
|
KR20190102059A
(ko)
*
|
2017-01-07 |
2019-09-02 |
메르크 파텐트 게엠베하 |
표적화된 TGF-β 억제를 위한 투약 레지멘 및 투여 형태
|
AR110755A1
(es)
|
2017-01-20 |
2019-05-02 |
Genzyme Corp |
Anticuerpos dirigidos a hueso
|
TWI787230B
(zh)
|
2017-01-20 |
2022-12-21 |
法商賽諾菲公司 |
抗TGF-β抗體及其用途
|
CA3051696A1
(en)
*
|
2017-02-01 |
2018-08-09 |
Acceleron Pharma Inc. |
Tgf.beta. and actrii antagonists for use in increasing immune activity
|
US11384154B2
(en)
|
2017-02-06 |
2022-07-12 |
Orionis Biosciences BV |
Targeted chimeric proteins and uses thereof
|
IL268198B1
(en)
|
2017-02-27 |
2024-06-01 |
Shattuck Labs Inc |
based chimeric proteins - TIGIT and LIGHT
|
JP7244428B2
(ja)
|
2017-02-27 |
2023-03-22 |
シャタック ラボ,インコーポレイテッド |
Vsig8ベースのキメラタンパク質
|
JP7121029B2
(ja)
|
2017-02-27 |
2022-08-17 |
シャタック ラボ,インコーポレイテッド |
Csf1rベースのキメラタンパク質
|
EP3589663A4
(en)
|
2017-03-02 |
2020-10-21 |
National Research Council of Canada |
TGF-ß RECEPTOR EECTODOMAN FUSION MOLECULES AND USES THEREOF
|
US20200150125A1
(en)
|
2017-03-12 |
2020-05-14 |
Yeda Research And Development Co., Ltd. |
Methods of diagnosing and prognosing cancer
|
WO2018167780A1
(en)
|
2017-03-12 |
2018-09-20 |
Yeda Research And Development Co. Ltd. |
Methods of prognosing and treating cancer
|
EP3600378A4
(en)
*
|
2017-03-24 |
2020-12-23 |
Orpheus Bioscience Inc. |
PANTIDS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS
|
CN107082812B
(zh)
*
|
2017-03-29 |
2018-11-13 |
上海科医联创生物科技有限公司 |
一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
|
CN110392692B
(zh)
|
2017-04-03 |
2023-07-21 |
豪夫迈·罗氏有限公司 |
抗pd-1抗体与突变体il-2或与il-15的免疫缀合物
|
AU2018247794A1
(en)
|
2017-04-05 |
2019-08-22 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies specifically binding to PD1 and LAG3
|
EP3615564A1
(en)
*
|
2017-04-24 |
2020-03-04 |
Alexion Pharmaceuticals, Inc. |
Antibody immune cell inhibitor fusion proteins
|
TW202402800A
(zh)
|
2017-05-01 |
2024-01-16 |
美商艾吉納斯公司 |
抗tigit抗體類和使用彼等之方法
|
HRP20230706T1
(hr)
*
|
2017-05-04 |
2023-10-13 |
Acceleron Pharma Inc. |
Fuzijski proteini tgf-beta receptora tipa ii i njihove upotrebe
|
CN110050000B
(zh)
|
2017-05-12 |
2022-07-26 |
苏州盛迪亚生物医药有限公司 |
含有TGF-β受体的融合蛋白及其医药用途
|
US20180325955A1
(en)
|
2017-05-12 |
2018-11-15 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
EP3625260A1
(en)
|
2017-05-16 |
2020-03-25 |
Bristol-Myers Squibb Company |
Treatment of cancer with anti-gitr agonist antibodies
|
IL312337A
(en)
|
2017-05-19 |
2024-06-01 |
Wuxi Biologics Shanghai Co Ltd |
Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), preparations containing them and uses thereof
|
WO2018213747A1
(en)
*
|
2017-05-19 |
2018-11-22 |
Merrimack Pharmaceuticals, Inc. |
4-1bb agonist and cd40 agonist bispecific molecules
|
JP2020521759A
(ja)
*
|
2017-05-26 |
2020-07-27 |
ザ・ジョンズ・ホプキンス・ユニバーシティ |
免疫トレランスを調節するための多機能性の抗体−リガンド・トラップ
|
US20210246227A1
(en)
|
2017-05-31 |
2021-08-12 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
JP2020522486A
(ja)
|
2017-06-01 |
2020-07-30 |
サイトメックス セラピューティクス インコーポレイテッド |
活性化可能抗pdl1抗体、およびその使用方法
|
CN107857819A
(zh)
*
|
2017-07-03 |
2018-03-30 |
江苏西迪尔生物技术有限公司 |
多功能融合蛋白及其应用
|
PL3661954T3
(pl)
|
2017-08-03 |
2022-05-16 |
Amgen Inc. |
Muteiny interleukiny 21 i sposoby leczenia
|
CN116333131A
(zh)
|
2017-08-04 |
2023-06-27 |
健玛保 |
与pd-l1和cd137结合的结合剂及其用途
|
CN107602705B
(zh)
*
|
2017-09-13 |
2018-08-31 |
北京鼎成肽源生物技术有限公司 |
一种基于蛋白互作用于检测细胞pd1表达情况的融合蛋白及其应用
|
US11834492B2
(en)
|
2017-09-27 |
2023-12-05 |
Epicentrx, Inc. |
Human IL-10 receptor alpha fusion proteins
|
AU2018338786A1
(en)
*
|
2017-09-29 |
2020-04-16 |
Nantcell, Inc. |
Antigenic proteins and methods therefor
|
KR20200074137A
(ko)
|
2017-10-10 |
2020-06-24 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Ctla-4 변이체 면역조절 단백질 및 이의 용도
|
EP3694885A1
(en)
|
2017-10-14 |
2020-08-19 |
CytomX Therapeutics, Inc. |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
CN111511391A
(zh)
*
|
2017-10-18 |
2020-08-07 |
英特拉克森公司 |
包含间隔区的多肽组合物
|
BR112020008978A2
(pt)
*
|
2017-11-09 |
2020-11-10 |
Medimmune, Llc |
polipeptídeos de fusão biespecíficos e seus métodos de uso
|
US20210198372A1
(en)
|
2017-12-01 |
2021-07-01 |
Juno Therapeutics, Inc. |
Methods for dosing and for modulation of genetically engineered cells
|
WO2019113123A1
(en)
*
|
2017-12-04 |
2019-06-13 |
Precithera, Inc. |
TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING
|
EP3720881A1
(en)
*
|
2017-12-08 |
2020-10-14 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
TW201930344A
(zh)
|
2018-01-12 |
2019-08-01 |
美商安進公司 |
抗pd-1抗體及治療方法
|
CN110151309B
(zh)
*
|
2018-02-14 |
2022-02-15 |
上海美杰医疗科技有限公司 |
多模态消融治疗术前规划方法及其设备
|
CA3093078A1
(en)
*
|
2018-03-06 |
2019-09-12 |
The Trustees Of The University Of Pennsylvania |
Prostate-specific membrane antigen cars and methods of use thereof
|
EA202091710A1
(ru)
|
2018-03-09 |
2021-02-16 |
Агенус Инк. |
Антитела против cd73 и способы их применения
|
WO2019178364A2
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
US20210238280A1
(en)
|
2018-03-14 |
2021-08-05 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
US11168138B2
(en)
*
|
2018-03-26 |
2021-11-09 |
Altor Bioscience, Llc |
Anti-PDL1, IL-15 and TGF-beta receptor combination molecules
|
KR20210011919A
(ko)
|
2018-04-17 |
2021-02-02 |
셀덱스 쎄라퓨틱스, 인크. |
항-cd27 항체 및 항-pd-l1 항체 및 이중특이적 작제물
|
AU2019262139A1
(en)
*
|
2018-05-03 |
2020-11-26 |
Acceleron Pharma Inc. |
Multispecific binders of TGFβ-superfamily ligands and uses thereof
|
AU2019262143A1
(en)
*
|
2018-05-03 |
2020-11-26 |
Acceleron Pharma Inc. |
Novel binders of TGFβ-superfamily ligands and uses thereof
|
CA3099079A1
(en)
*
|
2018-05-04 |
2019-11-07 |
Merck Patent Gmbh |
Combined inhibition of pd-1/pd-l1, tgf.beta. and dna-pk for the treatment of cancer
|
KR20210008502A
(ko)
|
2018-05-11 |
2021-01-22 |
크리스퍼 테라퓨틱스 아게 |
암을 치료하기 위한 방법 및 조성물
|
CA3103427A1
(en)
*
|
2018-06-15 |
2019-12-19 |
Acceleron Pharma Inc. |
Bi-and tri-functional fusion proteins and uses thereof
|
US11708401B2
(en)
|
2018-06-22 |
2023-07-25 |
Kite Pharma, Inc. |
Chimeric transmembrane proteins and uses thereof
|
AU2019293047A1
(en)
*
|
2018-06-29 |
2021-01-28 |
Gensun Biopharma Inc. |
Antitumor immune checkpoint regulator antagonists
|
CN112955465A
(zh)
|
2018-07-03 |
2021-06-11 |
马伦戈治疗公司 |
抗tcr抗体分子及其用途
|
KR20210042909A
(ko)
*
|
2018-07-09 |
2021-04-20 |
프레시전 인코포레이티드 |
융합 구조물 및 그의 이용 방법
|
EP3820887A4
(en)
*
|
2018-07-11 |
2022-04-20 |
KAHR Medical Ltd. |
PD1-4-1BBL FUSION PROTEIN VARIANT AND ITS USE
|
KR20210044220A
(ko)
|
2018-07-11 |
2021-04-22 |
카 메디컬 리미티드 |
SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법
|
US10780121B2
(en)
|
2018-08-29 |
2020-09-22 |
Shattuck Labs, Inc. |
FLT3L-based chimeric proteins
|
WO2020047329A1
(en)
*
|
2018-08-29 |
2020-03-05 |
Shattuck Labs, Inc. |
Chimeric proteins comprising extracellular domains and uses thereof
|
WO2020068653A1
(en)
|
2018-09-24 |
2020-04-02 |
Aerpio Pharmaceuticals, Inc. |
MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF
|
AU2019346645A1
(en)
|
2018-09-27 |
2021-04-29 |
Marengo Therapeutics, Inc. |
CSF1R/CCR2 multispecific antibodies
|
CN113302493A
(zh)
*
|
2018-10-01 |
2021-08-24 |
小利兰·斯坦福大学托管委员会 |
同时解析多种抗体同种型的高特异性和灵敏度免疫吸附诊断测定
|
IL282317B2
(en)
|
2018-10-17 |
2024-04-01 |
Biolinerx Ltd |
Treatment of metastatic adenocarcinoma of the pancreas
|
EP3873612A2
(en)
|
2018-11-01 |
2021-09-08 |
Merck Patent GmbH |
Methods of administering anti-tim-3 antibodies
|
EP3873611A1
(en)
|
2018-11-01 |
2021-09-08 |
Merck Patent GmbH |
Anti-tim-3 antibodies
|
EP3878461A4
(en)
|
2018-11-09 |
2022-08-17 |
Jiangsu Hengrui Medicine Co., Ltd. |
PHARMACEUTICAL COMPOSITION OF TGF-BETA RECEPTOR FUSION PROTEIN AND USE THEREOF
|
US20220025061A1
(en)
*
|
2018-12-10 |
2022-01-27 |
Bioxcel Therapeutics, Inc. |
Combination therapies for treating disease using an innate immunity modifier and an ox40 agonist
|
WO2020172605A1
(en)
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
JP2022523197A
(ja)
|
2019-02-21 |
2022-04-21 |
マレンゴ・セラピューティクス,インコーポレーテッド |
T細胞関連のがん細胞に結合する多機能性分子およびその使用
|
GB2599227B
(en)
|
2019-02-21 |
2024-05-01 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to T cells and uses thereof to treat autoimmune disorders
|
WO2020190725A1
(en)
|
2019-03-15 |
2020-09-24 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates targeting her2
|
BR112021019328A2
(pt)
|
2019-03-29 |
2021-11-30 |
Myst Therapeutics Llc |
Métodos ex vivo para produzir um produto terapêutico de célula t e composições e métodos relacionados
|
AU2020267057A1
(en)
|
2019-04-30 |
2021-11-18 |
Crispr Therapeutics Ag |
Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19
|
WO2020257823A2
(en)
*
|
2019-06-21 |
2020-12-24 |
Kite Pharma, Inc. |
TGF-β RECEPTORS AND METHODS OF USE
|
JP2022540571A
(ja)
*
|
2019-06-28 |
2022-09-16 |
ゲンスン バイオファーマ、インコーポレーテッド |
変異したTGFβ1-RII細胞外ドメインおよび免疫グロブリン足場で構成される抗腫瘍アンタゴニスト
|
US20220267442A1
(en)
*
|
2019-07-18 |
2022-08-25 |
Memorial Sloan Kettering Cancer Center |
METHODS AND COMPOSITIONS FOR TARGETING TGF-ß SIGNALING IN CD4+ HELPER T CELLS FOR CANCER IMMUNOTHERAPY
|
TW202120550A
(zh)
*
|
2019-08-08 |
2021-06-01 |
日商小野藥品工業股份有限公司 |
雙特異性蛋白質
|
WO2021037184A1
(zh)
*
|
2019-08-30 |
2021-03-04 |
正大天晴药业集团南京顺欣制药有限公司 |
一种靶向PD-L1和TGF-β的融合蛋白及其用途
|
CN110734498A
(zh)
*
|
2019-10-15 |
2020-01-31 |
上海科棋药业科技有限公司 |
一种用于解除免疫抑制的融合蛋白及其应用
|
US11802145B2
(en)
|
2019-10-21 |
2023-10-31 |
Nanjing Leads Biolabs Co., Ltd. |
Recombinant protein targeting PD-1 and TGFß
|
CN114728072A
(zh)
*
|
2019-10-23 |
2022-07-08 |
库尔生物制药有限公司 |
TGF-β多肽
|
WO2021093760A1
(zh)
*
|
2019-11-12 |
2021-05-20 |
江苏恒瑞医药股份有限公司 |
含有TGF-β受体的融合蛋白及其医药用途
|
US20230242675A1
(en)
*
|
2019-11-27 |
2023-08-03 |
Shanghai Epimab Biotherapeutics Co., Ltd. |
TGF[beta]/PD-L1 BISPECIFIC BINDING PROTEINS
|
US20230032934A1
(en)
|
2019-11-27 |
2023-02-02 |
Myst Therapeutics, Llc |
Method of producing tumor-reactive t cell composition using modulatory agents
|
CN113004414B
(zh)
*
|
2019-12-20 |
2022-09-06 |
广东菲鹏制药股份有限公司 |
抗PD1和TGFβ的双功能抗体及其制备方法,以及含有其的药物组合物
|
CN113121699A
(zh)
*
|
2019-12-30 |
2021-07-16 |
国典(北京)医药科技有限公司 |
Pttrap1双特异性融合蛋白及其应用
|
EP4084821A4
(en)
|
2020-01-03 |
2024-04-24 |
Marengo Therapeutics, Inc. |
CD33-BINDING MULTIFUNCTIONAL MOLECULES AND THEIR USES
|
CN115103685A
(zh)
*
|
2020-01-23 |
2022-09-23 |
格纳西尼有限公司 |
包含程序性细胞死亡配体1蛋白的融合蛋白及其用途
|
US11912751B2
(en)
*
|
2020-01-31 |
2024-02-27 |
Globetek Science Foundation |
Bi-functional fusion proteins comprised of TGF-B and immune checkpoint domains
|
MX2022010517A
(es)
|
2020-02-27 |
2022-11-14 |
Myst Therapeutics Llc |
Metodos para la expansion y enriquecimiento ex vivo de celulas t reactivas a tumor y composiciones relacionadas de las mismas.
|
US20230287081A1
(en)
*
|
2020-04-16 |
2023-09-14 |
Nantong Yichen Biopharma. Co. Ltd. |
PD-1 mutant polypeptide and preparation and application thereof
|
CA3180321A1
(en)
|
2020-04-24 |
2021-10-28 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
BR112022021785A2
(pt)
*
|
2020-04-28 |
2022-12-06 |
Sinocelltech Ltd |
Molécula truncada de domínio extracelular tgfbr2, proteína de fusão de molécula truncada de domínio extracelular tgfbr2 e anticorpo anti-egfr e uso antitumoral de proteína de fusão
|
CN111690070A
(zh)
*
|
2020-05-13 |
2020-09-22 |
深圳市众循精准医学研究院 |
一种sPD-1-Fc-sTGFβRII融合蛋白及其应用
|
US20230293530A1
(en)
|
2020-06-24 |
2023-09-21 |
Yeda Research And Development Co. Ltd. |
Agents for sensitizing solid tumors to treatment
|
CA3188596A1
(en)
*
|
2020-07-10 |
2022-01-13 |
Precigen, Inc. |
Fusion constructs and methods of using thereof
|
EP4204096A2
(en)
|
2020-08-26 |
2023-07-05 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
WO2022046920A2
(en)
|
2020-08-26 |
2022-03-03 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
GB2616354A
(en)
|
2020-08-26 |
2023-09-06 |
Marengo Therapeutics Inc |
Methods of detecting TRBC1 or TRBC2
|
WO2022057061A1
(en)
*
|
2020-09-16 |
2022-03-24 |
Suzhou Neologics Bioscience Co., Ltd. |
Pd-l1 antibodies, fusion proteins, and uses thereof
|
CN114539415B
(zh)
*
|
2020-11-24 |
2024-02-02 |
普米斯生物技术(珠海)有限公司 |
一种抗PD-L1/VEGF/TGF-β多特异性抗体及其用途
|
TW202304965A
(zh)
|
2021-05-04 |
2023-02-01 |
美商艾吉納斯公司 |
抗tigit抗體、抗cd96抗體及其使用方法
|
EP4373499A1
(en)
*
|
2021-07-21 |
2024-05-29 |
Mayo Foundation for Medical Education and Research |
Promoting immune surveillance against cancer cells
|
CA3230292A1
(en)
*
|
2021-08-27 |
2023-03-02 |
Theranotics Co., Ltd. |
Bispecific molecule specifically binding to b7-h3 and tgfb and uses thereof
|
IL312049A
(en)
|
2021-10-11 |
2024-06-01 |
Y Trap Inc |
Compositions and methods that inhibit IL-23 signaling
|
WO2023212691A1
(en)
*
|
2022-04-28 |
2023-11-02 |
Immatics US, Inc. |
DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF
|
WO2024006746A1
(en)
*
|
2022-06-29 |
2024-01-04 |
Cdres Pharma Llc |
Immunologically active polypeptide
|